Shopping Cart
- Remove All
- Your shopping cart is currently empty
Nepuvibart (ZRC3308-B10), an IgG1 type anti-SARS-CoV-2 monoclonal antibody, exhibits strong binding affinity to a distinct non-competing epitope on the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein. When combined in a 1:1 ratio with ZRC3308-A7, Nepuvibart is effective in preventing COVID-19 and in treating the early stages of the disease before it progresses to severe illness [1].
Pack Size | Price | Availability | Quantity |
---|---|---|---|
5 mg | Inquiry | Backorder | |
50 mg | Inquiry | Backorder |
Description | Nepuvibart (ZRC3308-B10), an IgG1 type anti-SARS-CoV-2 monoclonal antibody, exhibits strong binding affinity to a distinct non-competing epitope on the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein. When combined in a 1:1 ratio with ZRC3308-A7, Nepuvibart is effective in preventing COVID-19 and in treating the early stages of the disease before it progresses to severe illness [1]. |
Cas No. | 2640224-48-0 |
Storage | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.